Lifecore Biomedical, Inc. (LFCR)
(Delayed Data from NSDQ)
$7.87 USD
-0.06 (-0.76%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $7.86 -0.01 (-0.13%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum B VGM
Fundamental Charts
About Return on Equity (TTM)
Lifecore Biomedical, Inc.'s return on equity, or ROE, is -846.51% compared to the ROE of the Medical - Biomedical and Genetics industry of -66.95%. While this shows that LFCR has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
LFCR 7.87 -0.06(-0.76%)
Will LFCR be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for LFCR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LFCR
Lifecore Biomedical (LFCR) Soars 10.8%: Is Further Upside Left in the Stock?
Lifecore Biomedical (LFCR) Reports Q4 Loss, Tops Revenue Estimates
LFCR: What are Zacks experts saying now?
Zacks Private Portfolio Services
ImmunityBio (IBRX) Reports Q2 Loss, Tops Revenue Estimates
Lifecore Biomedical (LFCR) Reports Q3 Loss, Misses Revenue Estimates
Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Misses Revenue Estimates
Other News for LFCR
LFCR forms Bearish Engulfing on September 19
Is LFCR showing upside potential? New Uptrend shows up after gaining 2.99%
The technical outlook for LFCR is unchanged after it falls 2.04% on September 17
Is LFCR getting ready to pop? Calm After Storm shows up after gaining 2.34%
20 Day Moving Average Support appears for LFCR after 2.13% move